Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 16, 2012

Poll on the IPO Market This Year Has Voters Nearly Evenly Split

  • GEN poll voters were almost evenly split on whether they think the IPO window will swing open wider in 2012. When asked to forecast what the IPO market would look like this year, 51.1% thought there would be more IPO activity, 46.7% thought the window would remain narrow, and 2.2% were undecided.

    The number of IPOs in 2011 (13) was fewer than 2010 (16). Of the 26 IPIOs launched since 2010, two-thirds now trade at a loss to investors. However, some signs of hope exist, judging from a smaller percentage of firms discounting on their IPOs this year compared to last year as well as their post-IPO performance and the fact that of the two most recent biopharma companies to go public, one is trading above its IPO price, while another is unchanged.


Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »